search
Back to results

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

Primary Purpose

Asthma

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
SHR-1905/placebo
Sponsored by
Shanghai Hengrui Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial, and provides written informed consent, be able to comply with all the requirements and able to complete the study.
  2. Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form.
  3. Total body weight ≥ 45 kg, body mass index (BMI) between 18 and 28 kg/m2 at screening.
  4. For healthy subjects, no clinically significant abnormalities in medical history, general physical examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry, coagulation function and thyroid function) and ECG at the investigator's discretion during screening and baseline.

Exclusion Criteria:

  1. Known medical history of severe disease in cardiovascular, liver, kidney, digestive tract, mental, nerve, hematology, metabolic disorders, etc.
  2. Severe injuries or major surgeries within 6 months before screening or plan to do surgeries during the trial.
  3. Positive hepatitis B virus (HBsAg), hepatitis C virus (HCV-Ab), human immunodeficiency virus (HIV-Ab) at screening.
  4. Hyper/Hypotension which define as Systolic blood pressure (SBP) >140mmHg or <90mmHg, or Diastolic blood pressure (DBP)>90mmHg or <40mmHg at screening and at check in.
  5. Clinically significant abnormalities in 12-Lead ECG (e.g., For male QTcF > 450msec, for female QTcF > 470msec) at screening and at check in
  6. Positive alcohol breath test during baseline visit.
  7. Positive nicotine test during screening.
  8. Positive urine drug screen during screening.
  9. Participation in clinical trials of other investigational drugs or medical devices within 3 months prior to screening or within 5 half-lives of any drugs during screening visit, or in the follow-up period of a clinical study whichever is longer (according to the date of signed consent form) which is defined as have consented and used other investigational drugs (including placebo) or trial medical devices
  10. Any other circumstances that, in the investigator's judgment, may increase the risk to the subject, or associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response

Sites / Locations

  • Shanghai Xuhui Central HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Cohort 1

Cohort 2

Cohort 3

Cohort 4

Cohort 5

Cohort 6

Arm Description

A single subcutaneous injection of SHR-1905/placebo dose 1 in healthy subjects

A single subcutaneous injection of SHR-1905/placebo dose 2 in healthy subjects

A single subcutaneous injection of SHR-1905/placebo dose 3 in healthy subjects

A single subcutaneous injection of SHR-1905/placebo dose 4 in healthy subjects

A single subcutaneous injection of SHR-1905/placebo dose 5 in healthy subjects

A single subcutaneous injection of SHR-1905/placebo dose 6 in subjects with mild asthma

Outcomes

Primary Outcome Measures

Adverse events
Incidence and severity of adverse events

Secondary Outcome Measures

Pharmacokinetics-AUC0-last
Area under the concentration-time curve from time 0 to last time point after SHR-1905 administration
Pharmacokinetics-AUC0-inf
Area under the concentration-time curve from time 0 to infinity after SHR-1905 administration
Pharmacokinetics-Tmax
Time to Cmax of SHR-1905
Pharmacokinetics-Cmax
Maximum observed concentration of SHR-1905
Pharmacokinetics-CL/F
Apparent clearance of SHR-1905
Pharmacokinetics-V/F
Apparent volume of distribution during terminal phase of SHR-1905
Pharmacokinetics-t1/2
Terminal elimination half-life of SHR-1905
Anti-Drug antibody
The percentage of subjects with positive ADA titers over time for SHR-1905

Full Information

First Posted
May 26, 2021
Last Updated
October 8, 2021
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04905602
Brief Title
A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma
Official Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administered SHR-1905 in Healthy Subjects and Subjects With Mild Asthma.
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 15, 2021 (Actual)
Primary Completion Date
January 13, 2022 (Anticipated)
Study Completion Date
January 13, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study is a phase 1 single dose escalation study of SHR-1905 in healthy subjects and subjects with mild asthma. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1905 in healthy subjects and subjects with mild asthma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
62 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Experimental
Arm Description
A single subcutaneous injection of SHR-1905/placebo dose 1 in healthy subjects
Arm Title
Cohort 2
Arm Type
Experimental
Arm Description
A single subcutaneous injection of SHR-1905/placebo dose 2 in healthy subjects
Arm Title
Cohort 3
Arm Type
Experimental
Arm Description
A single subcutaneous injection of SHR-1905/placebo dose 3 in healthy subjects
Arm Title
Cohort 4
Arm Type
Experimental
Arm Description
A single subcutaneous injection of SHR-1905/placebo dose 4 in healthy subjects
Arm Title
Cohort 5
Arm Type
Experimental
Arm Description
A single subcutaneous injection of SHR-1905/placebo dose 5 in healthy subjects
Arm Title
Cohort 6
Arm Type
Experimental
Arm Description
A single subcutaneous injection of SHR-1905/placebo dose 6 in subjects with mild asthma
Intervention Type
Drug
Intervention Name(s)
SHR-1905/placebo
Intervention Description
Drug: SHR-1905 subcutaneous, single dose Drug: Placebo subcutaneous, single dose
Primary Outcome Measure Information:
Title
Adverse events
Description
Incidence and severity of adverse events
Time Frame
Start of Treatment to end of study (approximately 16 weeks)
Secondary Outcome Measure Information:
Title
Pharmacokinetics-AUC0-last
Description
Area under the concentration-time curve from time 0 to last time point after SHR-1905 administration
Time Frame
Start of Treatment to end of study (approximately 16 weeks)
Title
Pharmacokinetics-AUC0-inf
Description
Area under the concentration-time curve from time 0 to infinity after SHR-1905 administration
Time Frame
Start of Treatment to end of study (approximately 16 weeks)
Title
Pharmacokinetics-Tmax
Description
Time to Cmax of SHR-1905
Time Frame
Start of Treatment to end of study (approximately 16 weeks)
Title
Pharmacokinetics-Cmax
Description
Maximum observed concentration of SHR-1905
Time Frame
Start of Treatment to end of study (approximately 16 weeks)
Title
Pharmacokinetics-CL/F
Description
Apparent clearance of SHR-1905
Time Frame
Start of Treatment to end of study (approximately 16 weeks)
Title
Pharmacokinetics-V/F
Description
Apparent volume of distribution during terminal phase of SHR-1905
Time Frame
Start of Treament to end of study (approximately 16 weeks)
Title
Pharmacokinetics-t1/2
Description
Terminal elimination half-life of SHR-1905
Time Frame
Start of Treatment to end of study (approximately 16 weeks)
Title
Anti-Drug antibody
Description
The percentage of subjects with positive ADA titers over time for SHR-1905
Time Frame
Start of Treatment to end of study (approximately 16 weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial, and provides written informed consent, be able to comply with all the requirements and able to complete the study. Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form. Total body weight ≥ 45 kg, body mass index (BMI) between 18 and 28 kg/m2 at screening. For healthy subjects, no clinically significant abnormalities in medical history, general physical examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry, coagulation function and thyroid function) and ECG at the investigator's discretion during screening and baseline. Exclusion Criteria: Known medical history of severe disease in cardiovascular, liver, kidney, digestive tract, mental, nerve, hematology, metabolic disorders, etc. Severe injuries or major surgeries within 6 months before screening or plan to do surgeries during the trial. Positive hepatitis B virus (HBsAg), hepatitis C virus (HCV-Ab), human immunodeficiency virus (HIV-Ab) at screening. Hyper/Hypotension which define as Systolic blood pressure (SBP) >140mmHg or <90mmHg, or Diastolic blood pressure (DBP)>90mmHg or <40mmHg at screening and at check in. Clinically significant abnormalities in 12-Lead ECG (e.g., For male QTcF > 450msec, for female QTcF > 470msec) at screening and at check in Positive alcohol breath test during baseline visit. Positive nicotine test during screening. Positive urine drug screen during screening. Participation in clinical trials of other investigational drugs or medical devices within 3 months prior to screening or within 5 half-lives of any drugs during screening visit, or in the follow-up period of a clinical study whichever is longer (according to the date of signed consent form) which is defined as have consented and used other investigational drugs (including placebo) or trial medical devices Any other circumstances that, in the investigator's judgment, may increase the risk to the subject, or associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaoyu Yang
Phone
+86 18818211895
Email
xiaoyu.yang@hengrui.com
First Name & Middle Initial & Last Name or Official Title & Degree
Bo zhu
Phone
+86 13380043088
Email
bo.zhu@hengrui.com
Facility Information:
Facility Name
Shanghai Xuhui Central Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200031
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chen Yu, Bachelor
Phone
86-21-54030254
Email
cyu@shxh-centerlab.com

12. IPD Sharing Statement

Learn more about this trial

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

We'll reach out to this number within 24 hrs